What is HC Wainwright's Estimate for AARD Q2 Earnings?

Aardvark Therapeutics, Inc. (NASDAQ:AARD - Free Report) - Research analysts at HC Wainwright issued their Q2 2025 earnings estimates for Aardvark Therapeutics in a research report issued to clients and investors on Monday, June 30th. HC Wainwright analyst R. Selvaraju anticipates that the company will earn ($0.45) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $40.00 target price on the stock. HC Wainwright also issued estimates for Aardvark Therapeutics' Q3 2025 earnings at ($0.51) EPS, Q4 2025 earnings at ($0.58) EPS, FY2025 earnings at ($2.18) EPS, Q1 2026 earnings at ($0.77) EPS, Q2 2026 earnings at ($0.87) EPS, Q3 2026 earnings at ($0.80) EPS, Q4 2026 earnings at ($0.90) EPS and FY2026 earnings at ($3.34) EPS.

Aardvark Therapeutics (NASDAQ:AARD - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.70) by ($0.01).

A number of other equities research analysts also recently weighed in on the stock. Royal Bank Of Canada cut their price target on shares of Aardvark Therapeutics from $21.00 to $20.00 and set an "outperform" rating for the company in a report on Thursday, May 15th. Wall Street Zen downgraded shares of Aardvark Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, June 14th. Bank of America upped their price target on shares of Aardvark Therapeutics from $22.00 to $26.00 and gave the company a "buy" rating in a report on Thursday, March 27th. Cantor Fitzgerald reissued an "overweight" rating and issued a $50.00 price target on shares of Aardvark Therapeutics in a report on Tuesday, April 1st. Finally, Morgan Stanley began coverage on shares of Aardvark Therapeutics in a report on Monday, March 10th. They issued an "overweight" rating and a $29.00 price target for the company. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $33.00.

Aardvark Therapeutics Stock Up 3.0%

AARD stock traded up $0.40 during trading on Wednesday, hitting $13.92. The company had a trading volume of 10,562 shares, compared to its average volume of 81,073. The firm has a 50 day moving average price of $11.39. Aardvark Therapeutics has a fifty-two week low of $4.88 and a fifty-two week high of $19.58.

Institutional Trading of Aardvark Therapeutics

A number of hedge funds have recently bought and sold shares of AARD. Decheng Capital LLC purchased a new stake in Aardvark Therapeutics during the first quarter valued at about $29,419,000. Cormorant Asset Management LP purchased a new stake in Aardvark Therapeutics during the first quarter valued at about $6,009,000. Braidwell LP purchased a new stake in Aardvark Therapeutics during the first quarter valued at about $3,755,000. Adage Capital Partners GP L.L.C. purchased a new stake in Aardvark Therapeutics during the first quarter valued at about $1,878,000. Finally, Goldman Sachs Group Inc. purchased a new stake in Aardvark Therapeutics during the first quarter valued at about $153,000.

Aardvark Therapeutics Company Profile

Aardvark Therapeutics, Inc operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.